In reply-Coenzyme Q10 and Statin-Induced Myopathy

Mayo Clinic Proceedings

Volumn 90, Issue 3, 2015, Pages 420-421

  Banach, Maciej ^a   Mikhailidis, Dimitri P ^b  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; ANTINEOPLASTIC AGENT; CREATINE KINASE; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; THYROID HORMONE; UBIDECARENONE; CREATINE KINASE MM; UBIQUINONE;

CARDIOVASCULAR RISK; CREATINE KINASE BLOOD LEVEL; DRUG COMPETITION; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; HUMAN; HYPERLIPIDEMIA; LETTER; MYOPATHY; STATIN INDUCED MYOPATHY; SUPPLEMENTATION; UNSPECIFIED SIDE EFFECT; ANALOGS AND DERIVATIVES; BLOOD; MYALGIA;

CREATINE KINASE, MM FORM; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MYALGIA; UBIQUINONE;

EID: 84929048457     PISSN: 00256196     EISSN: 19425546     Source Type: Journal    
DOI: 10.1016/j.mayocp.2015.01.003     Document Type: Letter

References (7)

1. Banach M, Serban C, Sahebkar A, et al; Lipid and Blood Pressure Meta-Analysis Collaboration Group. Effects of coenzyme Q10 on statininduced myopathy: A meta-Analysis of randomized controlled trials. Mayo Clin Proc. 2015; 90(1):24-34.
2. Michalska-Kasiczak M, Sahebkar A, Mikhailidis DP, et al; Lipid and Blood Pressure Meta-Analysis Collaboration (LBPMC) Group. Analysis of vitamin D levels in patients with and without statin-Associated myalgiada systematic review and meta-Analysis of 7 studies with 2420 patients. Int J Cardiol. 2015;178: 111-116.
3. Vrablik M, Zlatohlavek L, Stulc T, et al. Statin-Associated myopathy: from genetic predisposition to clinical management. Physiol Res. 2014;63(suppl 3): S327-S334.
4. Garrido-Maraver J, Cordero MD, Oropesa-Ávila M, et al. Coenzyme Q10 therapy. Mol Syndromol. 2014; 5(3-4):187-197.
5. Cannon CP. IMPROVE-IT Trial: A comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes after acute coronary syndromes. Paper presented at: American Heart Association 2014 Scientific Sessions; November 17, 2014; Chicago, IL.
6. Dragan S, Serban MC, Banach M. Proprotein convertase subtilisin/kexin 9 inhibitors: An emerging lipid-lowering therapy [published online ahead of print June 17, 2014]? J Cardiovasc Pharmacol Ther. http://dx.doi.org/10.1177/1074248414539562.
7. Tziomalos K, Athyros VG, Mikhailidis DP. Statin discontinuation: An underestimated risk? Curr Med Res Opin. 2008;24(11):3059-3062.